HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 342 filers reported holding HALOZYME THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.30 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $984,834 | -80.3% | 25,781 | -81.4% | 0.00% | -83.3% |
| Q2 2023 | $4,990,465 | +586.2% | 138,355 | +626.5% | 0.02% | +500.0% |
| Q1 2023 | $727,290 | -87.8% | 19,044 | -81.8% | 0.00% | -90.6% |
| Q4 2022 | $5,958,340 | +154.0% | 104,716 | +96.4% | 0.03% | +88.2% |
| Q2 2022 | $2,346,000 | +468.0% | 53,329 | +425.3% | 0.02% | +240.0% |
| Q3 2021 | $413,000 | -58.2% | 10,153 | -53.3% | 0.01% | -54.5% |
| Q2 2021 | $987,000 | -52.7% | 21,732 | -56.6% | 0.01% | -66.7% |
| Q1 2021 | $2,087,000 | -20.5% | 50,054 | -18.6% | 0.03% | -10.8% |
| Q4 2020 | $2,626,000 | +713.0% | 61,492 | +401.0% | 0.04% | +640.0% |
| Q3 2020 | $323,000 | -29.6% | 12,273 | -28.3% | 0.01% | -28.6% |
| Q2 2020 | $459,000 | -65.0% | 17,111 | -76.8% | 0.01% | -82.9% |
| Q4 2019 | $1,310,000 | – | 73,897 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,305,403 | $233,209,000 | 10.86% |
| BB BIOTECH AG | 7,379,832 | $89,148,000 | 3.13% |
| SENZAR ASSET MANAGEMENT, LLC | 550,544 | $6,650,572,000 | 1.72% |
| SNYDER CAPITAL MANAGEMENT L P | 2,232,114 | $26,964,000 | 1.69% |
| Sterling Global Strategies LLC | 22,000 | $266,000 | 0.98% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 9,290,024 | $112,223,000 | 0.98% |
| MSD Partners, L.P. | 965,000 | $11,657,000 | 0.94% |
| DOHENY ASSET MANAGEMENT /CA | 130,950 | $1,582,000 | 0.81% |
| Taylor Wealth Management Partners | 128,110 | $1,548,000 | 0.69% |
| Bellevue Group AG | 318,000 | $3,841,000 | 0.69% |